Predicting outcomes and drug resistance with standardised treatment of active tuberculosis

European Respiratory Journal

Volumn 36, Issue 4, 2010, Pages 870-877

  Oxlade, O ^a,b   Schwartzman, K ^a,b   Pai, M ^a,b   Heymann, J ^b   Benedetti, A ^a,b   Royce, S ^c   Menzies, D ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acquired drug resistance; Modelling; Relapse; Treatment failure; Tuberculosis treatment

Indexed keywords

ETHAMBUTOL; ETHAMBUTOL PLUS ISONIAZID; ISONIAZID; ISONIAZID PLUS RIFAMPIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; DEATH; DRUG RESISTANCE; DRUG TREATMENT FAILURE; HUMAN; MULTIDRUG RESISTANT TUBERCULOSIS; PREDICTION; PREVALENCE; PRIORITY JOURNAL; RELAPSE; RISK ASSESSMENT; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; TUBERCULOSIS; VALIDATION STUDY;

COHORT STUDIES; COMMUNICABLE DISEASE CONTROL; DRUG RESISTANCE, BACTERIAL; HIV INFECTIONS; HUMANS; ISONIAZID; PYRAZINAMIDE; RECURRENCE; RIFAMPIN; TREATMENT OUTCOME; TUBERCULOSIS, MULTIDRUG-RESISTANT; WORLD HEALTH;

EID: 77957840635     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00151709     Document Type: Article

References (19)

1. World Health Organization. Treatment of Tuberculosis: Guidelines for National ProgrammesWHO/CDS/TB/2008 (Revised June 2008). 3rd Edn. Geneva, World Health Organization, 2008; p. 313.
2. Enarson DA, Rieder HL, Arnadottir T, et al. Tuberculosis guide for low income countries. 3rd Edn. Paris, International Union Against Tuberculosis and Lung Disease, 2000.
3. World Health Organization. Global Tuberculosis Control. Surveillance, Planning, Financing: 2008 Report No.: (WHO/HTM/TB/2006.362). Geneva, World Health Organization, 2008.
4. Menzies D, Benedetti A, Paydar A, et al. Effect of duration and intermittency of rifampin on tuberculosis treatment outcomes: a systematic review and meta-analysis. PLOS Med 2009; 6: e1000146.
5. World Health Organization. Treatment of Tuberculosis Guidelines: 4th Edn Report No.: WHO/HTM/TB/2009.420. Geneva, World Health Organization, 2010.
6. Menzies D, Benedetti A, Paydar A, et al. Standardized treatment of active tuberculosis in patients with previous treatment and/or with mono-resistance to isoniazid: a systematic review and meta-analysis. PLOS Med 2009; 6: e1000150.
7. Rouillon A. The mutual assistance programme of the IUATLD. Development, contribution and significance. Bull Int Union Tubec Lung Dis 1991; 66: 159-172.
8. Espinal MA Time to abandon the standard retreatment regimen with first-line drugs for failures of standard treatment, Int J Tuberc Lung Dis 2003; 7: 607-608.
9. Espinal M, Raviglione MC. From threat to reality: the real face of multidrug-resistant tuberculosis. Am J Resp Crit Care Med 2008; 178: 216-217.
10. Mak A, Thomas A, Granado M, et al. Influence of multidrug resistance on tuberculosis treatment outcomes with standardized regimens. Am J Respir Crit Care Med 2008; 178: 306-312. 2008.
11. Quy HTW, Lan NTN, Borgdorff MW, et al. Drug resistance among failure and relapse cases of tuberculosis: is the standard retreatment regimen adequate? Int J Tuberc Lung Dis 2003; 7: 631-636.
12. Yoshiyama T, Yanai H, Rhiengtong D, et al. Development of acquired drug resistance in recurrent tuberculosis patients with various previous treatment outcomes. Int J Tuberc Lung Dis 2004; 8: 31-38. (Pubitemid 38120703)
13. World Health Organization. Anti-tuberculosis drug resistance in the world report number 4 Report No.: WHO/HTM/TB/2008. Geneva, World Health Organization, 2008. Available from: whqlibdoc.who.int/publications/2008; 2008.
14. Becerra MC, Freeman J, Bayona J, et al. Using treatment failure under effective directly observed short-course chemotherapy programs to identify patients with multidrug-resistant tuberculosis. Int J Tuberc Lung Dis 2000; 4: 108-114. (Pubitemid 30123642)
15. Trébucq A, Anagonou S, Gninafon M, et al. Prevalence of primary and acquired resistance of Mycobacterium tuberculosis to antituberculosis drugs in Benin after 12 years of short-course chemotherapy. Int J Tuber Lung Dis 1999; 3: 466-470.
16. Khan FA, Minion J, Pai M, et al. Treatment of active tuberculosis in HIV co-infected patients: a systematic review and meta-analysis. Clin Infect Dis 2010; 50: 1288-1299.
17. Vernon A, Burman W, Benator D, et al. Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium. Lancet 1999; 353: 1843-1847. (Pubitemid 29251017)
18. Lew W, Oxlade O, Pai M, et al. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis. Ann Intern Med 2008; 149: 123-134.
19. Rieder HL. Epidemiologic Basis of Tuberculosis Control. 1st Edn. Paris, International Union Against Tuberculosis and Lung Disease, 1999; pp. 1-162.